UA101341C2 - Normal;heading 1;heading 2;heading 3;THERAPEUTIC USES OF COMPOUNDS HAVING COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITY - Google Patents

Normal;heading 1;heading 2;heading 3;THERAPEUTIC USES OF COMPOUNDS HAVING COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITY

Info

Publication number
UA101341C2
UA101341C2 UAA201007110A UAA201007110A UA101341C2 UA 101341 C2 UA101341 C2 UA 101341C2 UA A201007110 A UAA201007110 A UA A201007110A UA A201007110 A UAA201007110 A UA A201007110A UA 101341 C2 UA101341 C2 UA 101341C2
Authority
UA
Ukraine
Prior art keywords
heading
compounds
normal
therapeutic uses
ht1a activity
Prior art date
Application number
UAA201007110A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Николас Мур
Марианна Драгхейм
Анейл Батра
Джин Чон
Original Assignee
Х. Луннбек А/С
Такеда Фармасьютикалз Норт Америка, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Луннбек А/С, Такеда Фармасьютикалз Норт Америка, Инк filed Critical Х. Луннбек А/С
Priority claimed from PCT/DK2008/050271 external-priority patent/WO2009062517A1/en
Publication of UA101341C2 publication Critical patent/UA101341C2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

New pharmaceutical uses of l-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.
UAA201007110A 2007-11-13 2008-11-12 Normal;heading 1;heading 2;heading 3;THERAPEUTIC USES OF COMPOUNDS HAVING COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITY UA101341C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200701607 2007-11-13
PCT/DK2008/050271 WO2009062517A1 (en) 2007-11-13 2008-11-12 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Publications (1)

Publication Number Publication Date
UA101341C2 true UA101341C2 (en) 2013-03-25

Family

ID=51585271

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201007110A UA101341C2 (en) 2007-11-13 2008-11-12 Normal;heading 1;heading 2;heading 3;THERAPEUTIC USES OF COMPOUNDS HAVING COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITY

Country Status (1)

Country Link
UA (1) UA101341C2 (en)

Similar Documents

Publication Publication Date Title
MX2010004688A (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity.
HRP20120173T1 (en) 1- ¦[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
MX2009014208A (en) Heterocyclic compounds and use thereof as erk inhibitors.
UA97392C2 (en) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of pain
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
GEP20135730B (en) Trans-4-{2-[4-(2,3-dichlorophe-nyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treatment of schizophrenia
UA102517C2 (en) Substituted morpholine and thiomorpholine derivatives, pharmaceutical composition based thereon and use thereof for the preparation of medicament for the treatment of a disorder or disease of the central nervous system
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
RS50624B (en) Monohydrochloride salt of 1- [3- [3- (4-chlorophenyl) propoxy] propyl] -piperidine
TN2011000504A1 (en) Liquid formulations of salts of 1-[2-(2,4- dimethylphenylsulfanyl) phenyl] piperazine
UA101323C2 (en) Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for the treatment of acute mania
RS53521B1 (en) Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
SMT201300108B (en) New compositions of 1-Ä2- (2,4-dimethylphenyl sulfanil) -phenylÜ piperazine
NO20082112L (en) 3-Amino-2-arylpropylazaindoles and their use
SG155181A1 (en) Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
TW200732304A (en) Piperidine derivatives
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
TW200700390A (en) Metabolites for nk-1 antagonists for emesis
MX349724B (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]pipe razine.
UA101341C2 (en) Normal;heading 1;heading 2;heading 3;THERAPEUTIC USES OF COMPOUNDS HAVING COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITY
MY145425A (en) Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
TW200519098A (en) Succinate and malonate salt of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-yl)-1, 2, 2-trimethylpiperazine and the use as a medicament
AU2016202490A1 (en) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
NO20064112L (en) Pharmaceutical dosage forms and preparations